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April 15, 2008:1507–11ften required and are complicated by the use of anticoagula-
ion. Accordingly, all patients in this series underwent pericar-
ial bioprosthetic valve replacement in the tricuspid and pul-
onic positions.
Involvement of left-sided valves is rare and has been associated
ith the presence of an intracardiac shunt, endobronchial tumor
ocalization, or a high tumor activity. Connolly et al. (7), in the
nly published series specifically focused on left-sided CHD, noted
he absence of a PFO in 6 of 11 patients. Among these patients,
he authors reported higher levels of 5-HIAA. We observed a
FO in one-third of patients with left-sided valve involvement.
nterestingly, both patients without a PFO presented with the
ighest urinary 5-HIAA levels, potentially suggesting major tumor
ctivity. In contrast to right-sided CHD, the optimal surgical
pproach for left-sided valvular disease remains debatable. Our
xperience suggests that left-sided lesions may be less advanced
ompared with those on the right side. In these patients with
oderate left-sided valvular lesions, we elected to perform recon-
tructive surgery. Late echocardiography has shown only mild valvular
egurgitation, indicating that in selected cases these techniques can be
erformed safely with good midterm results.
avier G. Castillo, MD
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1:I36–40.Letters to the Editorsefulness of
9mTc-DPD Scintigraphy
n Cardiac Amyloidosis
n their useful state-of-the-art paper on the evaluation and manage-
ent of cardiac amyloidosis, Selvanayagam et al. (1) rightly dedicate
uch space to noninvasive evaluation but make no mention of
relevant imaging tool: 99mTc-3,3-diphosphono-1,2-propano-
icarboxylic acid (99mTc-DPD) scintigraphy. The authors do discuss
adiolabeled serum amyloid P component (SAP) scintigraphy, which
an provide valuable information on the distribution and extent of
myloid deposition in the body as a whole, but (as the authors point
ut) cannot adequately image amyloid in the heart. Unlike the SAP
echnique, 99mTc-DPD scintigraphy is capable of imaging amyloid
eposition in the myocardium of patients with transthyretin-related
TTR) amyloidosis (i.e., hereditary systemic amyloidosis and senile
ystemic amyloidosis) (2–5). This specific imaging characteristic may
acilitate differential diagnosis between TTR and AL cardiac amy-
oidosis in routine practice—a clinically relevant distinction (5).
ecause 99mTc-DPD scintigraphy is a standardized technique that
ses a widely available tracer, we think that this noninvasive exami-
ation should be known to all clinicians involved in the diagnosis andClaudio Rapezzi, MD
ierluigi Guidalotti, MD
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etizia Riva, MD
nrica Perugini, MD, PhD
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diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-
1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol
2005;46:1076–84.
eply
e welcome the interest of Drs. Rapezzi and colleagues in our
rticle (1). We did not discuss radionuclide imaging of amyloid
ith tracers developed for bone scintigraphy because few data are
vailable and because of constraints of space. Bone scintigraphy in
myloidosis has been evaluated systematically only in very small
eries (2), and there is no evidence as yet for a specific molecular
nteraction between bone-seeking isotopes and amyloid deposits.
e believe that the suggestions by Dr. Rapezzi and colleagues that
one scintigraphy can facilitate the differential diagnosis of
ransthyretin and AL cardiac amyloidosis is therefore unsubstan-
iated in light of present knowledge but that further investigation
f this interesting phenomenon is warranted.
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s Computed
omographic Angiography
rognostic in Patients
ith Cardiac Symptoms?
n the September 18, 2007, issue of the Journal, Min et al. (1)
eported the results of their registry analysis of 1,127 patients with
ardiac symptoms undergoing 16-slice coronary computed tomo-
raphic angiography. Their results suggest that all-cause mortality
ay be predicted by the results of computed tomographic angiog-
aphy and the use of a simplified coronary plaque scoring system.
f replicated, this study will be viewed as an important contribution
o the field of cardiology.
There is one major issue we would like to raise. A substantial
umber of patients had moderate to severe triple-vessel coronary
rtery disease. We assume most of these patients underwent mevascularization that may well have affected their 15-month
ll-cause mortality and confounded interpretation of the data. This
as also pointed out by the editorialist, John J. Mahmarian, MD
2). In a single-center, registry trial, the revascularization proce-
ures and outcomes should be readily obtained and reported.
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eply
e thank Drs. Suhar, Hitchcock, Russo, and Topol for their
nterest in our recent report of the prognostic value of coronary
omputed tomographic angiography (CCTA) for the prediction of
ll-cause death (1). Suhar and colleagues raise the possibility that
ost patients in our study population with moderate to severe
riple-vessel coronary artery disease may have undergone coronary
evascularization that might have affected their mortality. In response
o this important question, we have further evaluated data now
vailable to us at the primary sites from which patients were
eferred. Among the 106 patients with CCTA-identified moderate
o severe 3-vessel coronary artery disease (defined by severe plaque
n the proximal or midportions of the left anterior descending
rtery/diagonal branch and left circumflex artery/obtuse marginal
ranch and right coronary artery, or moderate to severe plaque in
he left main artery), 37 underwent subsequent invasive coronary
ngiography, with 6 undergoing percutaneous or surgical revascu-
arization. No significant difference existed in all-cause mortality
etween the small groups of patients who underwent invasive
ngiography or coronary revascularization and the larger number
ho did not (both p  0.20 in univariate analyses).
As Suhar and colleagues also correctly note, these results represent
ntermediate-term outcomes based upon CCTA findings from 16-
lice CCTA scans, for which long-term mortality data is only just
eginning to unfold (2). Our study represents the scaling of only the
rst of many hurdles to come. Future prognostic series examining the
fficacy of current generation 64-slice CCTA plaque identification for
he prediction of future adverse outcome, including major cardiovas-
ular events other than death, are necessary at this early stage in the
eld. Furthermore, additional information that can be routinely
leaned from a typical CCTA examination, including plaque
omposition patterns (3); cardiac chamber function, volumes, and
ass (4); and myocardial attenuation densities (5) should be
